Friday, 21 Jul 2017

You are here

FDA Approves Tremfya (guselkumab) for Plaque Psoriasis

The U.S. Food and Drug Administration (FDA) has approved the IL-23 inhibitor, Tremfya (guselkumab), for patients with moderate to severe plaque psoriasis.

The drug received an expedited regulatory review following application of an FDA Priority Review Voucher.

After loading doses at weeks 0 and 4, guselkumab is given as 100 mg subcutaneously (prefilled syringe) every eight weeks. In clinical studies, patients receiving Tremfya experienced significant improvement in skin clearance and greater improvement in symptoms of plaque psoriasis including itch, pain, stinging, burning and skin tightness when compared with placebo at week 16.

The clinical development program included more than 2,000 patients in the Phase 3 VOYAGE 1, VOYAGE 2 and NAVIGATE studies, which have been previously presented or published in peer-reviewed journals. In a head-to-head trial, guselkumab beat adalimumab (ADA) with PASI90 results of 73% compted to 2.9% on placebo and 50% percent on ADA.

The NAVIGATE study tested the effectiveness of Tremfya in patients who had an inadequate response to ustekinumab and found 28-31% of Tremfya-treated patients were considered cleared or almost cleared versus 14% of UST treated patients at 12 weeks.

There are no contraindications or boxed warnings. Most common (≥1%) adverse reactions associated with Tremfya include upper respiratory infections, headache, injection site reactions, arthralgia,diarrhea, gastroenteritis, tinea infections, and herpes simplex infections. Elevated hepatic enzymeswere reported more frequently in the Tremfya group (2.6%) than in the placebo patients (1.9%). 

Guselkumab has been shown to be ineffective in rheumatoid arthritis, and is currently under study in psoriatic arthritis and ankylosing spondylitis. 

The addition of Tremfya will crowd a growing market for psoriatic therapies and will compete with existing approve therapies including the TNF inhibitiors, the IL-17 inhibitors (secukinumab, ixekizumab) and apremilast. Next month, the FDA will convene a hearing over the application to approve tofacitinib for psoriatic arthritis.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Obesity Impairs TNF Inhibitor Responses in Axial Spondyloarthritis

Investigators with the Swiss Clinical Quality Management (SCQM) program have studied the effects of obesity on patients with axial spondyloarthritis (axSpA) and, specifically, their response to tumor necrosis factor inhibitors (TNFi).

Statins Improve Survival in Ankylosing Spondylitis

Systemic inflammation (from underling inflammatory polyarthritis) clearly accelerates atherosclerosis with a resultant increase risk of cardiovascular disease.

Orencia Approved for Use in Psoriatic Arthritis

The FDA has approved both IV and SC ORENCIA (abatacept) for the treatment of adults with active Psoriatic Arthritis.

IV Golimumab in Psoriatic Arthritis

Based on recent clinical trials, the makers of golimumab have petitioned the FDA for new indications in PsA and AS. Trials for PsA (GO-VIBRANT) and AS (GO-ALIVE) were presented at last weeks EULAR 2017 meeting in Madrid, Spain.

Tildrakizumab, an IL-23 Inhibitor, is Successful in Plaque Psoriasis

Therapeutic options for cutaneous psoriasis (and psoriatic arthritis as well) are rapidly expanding.  Lancet has published the impressive results of two phase III trials of tildrakizumab, a IgG1 antibody against interleukin 23 p19, in patients with active chronic plaque psoriasis.